EPA Confirms No Cancer Link for Roundup, but Public Concerns Persist

The U.S. Environmental Protection Agency (EPA) has reaffirmed its assessment that glyphosate, the active ingredient in Roundup, is “not likely to be carcinogenic to humans,” according to a May 2023 final determination. However, the agency’s findings have not quelled ongoing debates about the herbicide’s safety, particularly following a 2015 classification by the World Health Organization’s International Agency for Research on Cancer (IARC) that grouped glyphosate with “probably carcinogenic” substances.

EPA’s Latest Assessment on Roundup and Cancer

The EPA’s May 2023 review concluded that glyphosate does not pose a cancer risk to humans, citing “no conclusive evidence of carcinogenicity” from extensive studies. This aligns with the agency’s previous evaluations, which have consistently found that glyphosate is safe when used according to label instructions. The decision followed a multi-year analysis of peer-reviewed research, including data from the U.S. Department of Health and Human Services and the European Food Safety Authority.

Despite the EPA’s stance, the IARC’s 2015 classification of glyphosate as a Group 2A carcinogen—meaning it is “probably carcinogenic to humans”—has fueled public skepticism. The IARC’s assessment highlighted potential links to non-Hodgkin lymphoma, though it acknowledged limitations in the available data. The agency noted that “the evidence is limited” but emphasized the need for further research.

Scientific Debate and Public Concerns

The discrepancy between the EPA and IARC findings has created a polarized scientific landscape. A 2021 meta-analysis published in *Environmental Health Perspectives* found a “modest association” between glyphosate exposure and non-Hodgkin lymphoma, though the study’s authors cautioned that confounding factors, such as pesticide use patterns, could influence the results. Meanwhile, the National Cancer Institute has stated that “current evidence does not support a link between glyphosate and cancer.”

Public concerns have also been amplified by legal cases. In 2020, a California jury awarded $2 billion to a school groundskeeper who claimed Roundup caused his non-Hodgkin lymphoma. Although the ruling was later reduced to $78 million, it underscored the ongoing controversy. Bayer AG, which acquired Monsanto (the developer of Roundup) in 2018, has faced over 100,000 lawsuits alleging the herbicide causes cancer. The company maintains that glyphosate is safe and has appealed multiple rulings.

What This Means for Consumers and Regulators

For consumers, the EPA’s determination suggests that Roundup, when used as directed, does not pose a significant cancer risk. However, the agency advises caution, noting that “glyphosate can be harmful if misused or handled improperly.” This includes avoiding inhalation of the herbicide and following application guidelines to minimize exposure.

Regulatory approaches vary globally. The European Union has imposed stricter restrictions on glyphosate, with some member states, like Germany, pushing for a ban by 2023. In contrast, the U.S. and Brazil have maintained broader approvals. The divergence highlights the challenge of reconciling scientific uncertainty with public health policy.

Experts emphasize that the risk of cancer from glyphosate is likely low for the general population, given the limited exposure through agricultural use. However, farmers and agricultural workers, who handle the herbicide more frequently, may face higher risks. The EPA recommends protective measures, such as wearing gloves and avoiding spraying on windy days.

Looking Ahead: Ongoing Research and Policy Shifts

Research into glyphosate’s health effects continues, with the National Institute of Environmental Health Sciences funding studies on long-term exposure. A 2022 report by the U.S. Government Accountability Office called for “more transparency” in the EPA’s risk assessments, citing gaps in data on vulnerable populations, such as children and pregnant individuals.

As regulatory frameworks evolve, the debate over Roundup underscores the complexities of balancing scientific evidence, public perception, and policy. While the EPA’s latest assessment provides clarity for some, the broader conversation about pesticide safety remains active, with stakeholders urging further research and stricter safety protocols.